Symvivo

News

Announcing Research Collaboration with Merck

Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivo’s bacTRL™ platform technology for use in advancing delivery of oral vaccines.

January 5, 2021

Announcing Research Collaboration with Janssen

Under the terms of the agreement, Janssen will have the exclusive option to research, develop and commercialize novel biological therapeutic candidates based on Symvivo’s bacTRL™ platform technology.

November 24, 2020

CTV News - Symvivo's COVID-19 vaccine candidate begins clinical trial in Australia

Symvivo CEO and founder Alexander Graves told CTVNews.ca the vaccine candidate has a scientific and compliance benefit.

November 5, 2020

First Healthy Volunteer Dosed in Phase 1 Clinical Trial of Symvivo's Oral COVID-19 Vaccine Candidate

Symvivo announces the enrollment and dosing of the first healthy volunteer in a clinical trial in Australia evaluating its bacTRL-Spike™ oral vaccine candidate for the prevention of COVID-19.

November 2, 2020

Symvivo Receives Funding for COVID-19 Vaccine Program

Contribution of up to $2.8 million will support clinical advancement of bacTRL-Spike™ oral vaccine candidate.

October 20, 2020

First-in-Human Trial of Symvivo’s Oral COVID-19 Vaccine Candidate, bacTRL-Spike™

Symvivo Corporation has received regulatory approval to initiate a Phase 1, first-in-human trial of bacTRL-Spike™, an oral DNA vaccine candidate for the prevention of COVID-19.

October 19, 2020

Appointment of Lloyd Mackenzie as President and Chief Operating Officer

Announcing the appointment of Lloyd Mackenzie as the company’s President and Chief Operating Officer.

September 16, 2020

TOPICS